For millions of people living with the lingering effects of SARS-CoV-2, the most debilitating symptom is often not a respiratory issue, but a crushing, systemic exhaustion that resists sleep and exercise. This profound fatigue, a hallmark of post-acute sequelae of SARS-CoV-2 (PASC), has long lacked a targeted pharmacological solution, leaving patients and providers to rely largely on symptom management and pacing.
Latest evidence suggests a potential path forward. A randomized adaptive trial published March 31 in the Annals of Internal Medicine found that fluvoxamine, an antidepressant with unique anti-inflammatory properties, significantly reduces fatigue and improves the overall quality of life for those struggling with long COVID.
The findings provide some of the first robust clinical evidence that a specific medication can alleviate the persistent lethargy associated with the condition. While other drugs, including the diabetes medication metformin, were tested in the same study, they did not produce the same beneficial results for fatigue.
As a physician, I have seen how the “brain fog” and physical exhaustion of long COVID can strip a person of their autonomy, making simple tasks like grocery shopping or working a full day experience impossible. The search for a medical intervention that moves beyond “lifestyle adjustment” is urgent, and this study brings the medical community closer to a standardized treatment protocol.
A Comparative Approach to Long COVID Fatigue
The study, led by Gilmar Reis, M.D., Ph.D., of McMaster University in Hamilton, Ontario, and Jamie Forrest, Ph.D., of the University of British Columbia, utilized a randomized adaptive design to test two different pharmacological candidates against a placebo. The researchers enrolled 399 adults who had experienced persistent fatigue for 90 days or more following a confirmed COVID-19 infection.
Participants were randomly assigned to one of three groups for a 60-day treatment period: fluvoxamine (100 mg twice daily), metformin (750 mg twice daily), or a matching placebo. By using an adaptive trial design, the researchers could more efficiently evaluate which intervention was showing the most promise.
The primary measure of success was the Fatigue Severity Scale, a validated tool used to quantify the impact of fatigue on daily functioning. The results showed a clear divergence between the treatment groups.
| Treatment Group | Fatigue Reduction (Day 60) | Sustained Effect (Day 90) | Adverse Event Rate |
|---|---|---|---|
| Fluvoxamine | Significant (-0.43 mean diff) | Sustained (-0.58 mean diff) | 20.0% |
| Metformin | No significant benefit | No significant benefit | 28.8% |
| Placebo | Baseline | Baseline | 29.7% |
Beyond the Numbers: Quality of Life
While the reduction in fatigue scores was the primary endpoint, the researchers also looked at the broader “quality of life” (QoL) metrics. The study found a high posterior probability that fluvoxamine improved the general well-being and daily functioning of the participants.
Notably, the benefits of fluvoxamine appeared to persist even after the 60-day treatment window closed. The mean difference in fatigue scores actually improved further by day 90, suggesting a lasting modulation of the body’s inflammatory or neurological response rather than a temporary masking of symptoms.
“This trial gives clinicians their first strong evidence for a medication that helps reduce long COVID fatigue,” Jamie Forrest said in a statement. “Patients want something they can try today – and this finding brings us closer to that reality.”
Why Fluvoxamine? Understanding the Mechanism
To the casual observer, using an antidepressant to treat physical fatigue might seem counterintuitive. However, fluvoxamine is not acting here as a traditional SSRI (selective serotonin reuptake inhibitor) for mood elevation. Instead, researchers have focused on its role as a sigma-1 receptor agonist.
The sigma-1 receptor is involved in regulating the cellular stress response and reducing the production of pro-inflammatory cytokines. Since long COVID is widely believed to be driven by persistent inflammation or an autoimmune-like response, fluvoxamine’s ability to “quiet” this inflammation may be what allows patients to regain their energy.
The safety profile in this trial was also encouraging. Adverse events were actually less frequent in the fluvoxamine group (20.0%) than in either the metformin group (28.8%) or the placebo group (29.7%). Severe adverse events (grade 3 or higher) were rare across all cohorts, suggesting the drug was well-tolerated at the studied dosage.
Clinical Caveats and Next Steps
Despite the promising data, the medical community generally views such findings as a stepping stone rather than a final cure. The study noted that one author had ties to the biopharmaceutical industry, a standard disclosure that reminds clinicians to seem for independent replication of the results.
because long COVID is a heterogeneous condition—meaning it affects different people in vastly different ways—We see unlikely that a single drug will work for everyone. The failure of metformin to show significant benefit in this specific trial highlights that metabolic interventions may not be the answer for all types of PASC-related fatigue.
For patients, the immediate takeaway is that there is now a peer-reviewed, randomized evidence base that their doctors can reference. However, fluvoxamine is a prescription medication that can interact with other drugs, and it should only be initiated under strict medical supervision.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.
The next phase for this research likely involves larger-scale phase III trials to confirm these findings across more diverse populations and to determine the optimal long-term dosing strategy. Updated clinical guidelines for the management of PASC are expected to evolve as more data on sigma-1 agonists becomes available.
Do you or a loved one struggle with long COVID fatigue? Share your experience in the comments or share this article with someone who needs to know about these new developments.
